Onkológia 5/2022

Current trends in the treatment of pancreatic cancer

research, prognosis of patients with pancreatic ductal adenocarcinoma (PDAC) has not improved significantly in the past decades. Inovative therapies did not show effectivity in the treatment of these patients. In patients with PDAC, harboring mutations in the homologous recombination (HRD) genes, better specifications of patients who could profit from this treatment is necessary. Due to the frequency of K-RAS (kirsten rat sarcoma virus) mutations, extensive efforts have been made to target this abberation, meanwhile first covalent inhibitors are already being investigated in clinical trials. On the other hand, K-RAS wild type tumors offer opportunities to target aberrant signalling pathways.

Keywords: PDAC, immonotherapy, targeted therapy, K-RAS